Skip to content

Post-market Observational Clinical Study With the Medical Device 'SPHEREPLAST'

Post-market Observational Clinical Study With the Medical Device 'SPHEREPLAST' (SPHERE Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07242677
Enrollment
37
Registered
2025-11-21
Start date
2026-02-03
Completion date
2026-04-22
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic Fractures, Vertebra Compression Fracture

Brief summary

This is a retrospective, single-centre, single-arm post-market observational study evaluating the safety and clinical performance of the SPHEREPLAST medical device used in balloon kyphoplasty procedures for the treatment of traumatic and osteoporotic vertebral compression fractures (VCFs). SPHEREPLAST is a titanium alloy (Ti6Al4V-ELI) trabecular sphere system designed to stabilise the vertebral body structure after balloon kyphoplasty, providing immediate mechanical stability and promoting bone ingrowth. The study includes 40 adult patients who have been treated with SPHEREPLAST for thoracolumbar VCFs (A1, A3, OF2, OF3). Data will be collected retrospectively from medical records at four timepoints: pre-operative (baseline), within five days after surgery, at one month, and at one year post-surgery. The primary endpoints are the changes in pain intensity (Numerical Rating Scale, NRS) and disability (Oswestry Disability Index, ODI) between baseline and 1-year follow-up. Secondary endpoints include radiographic outcomes (kyphotic angle, wedge angle, vertebral body height) and the incidence of adverse events related to the device or the procedure. The aim of the study is to assess the real-world clinical efficacy and safety of SPHEREPLAST as an alternative to bone cement in kyphoplasty, with specific attention to pain control, functional recovery, and vertebral stability.

Interventions

None listed

Sponsors

MT Ortho s.r.l.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients treated with SPHEREPLAST for post-traumatic thoracolumbar VCFs A1 and A3, osteoporotic OF2 and OF3; * Complete availability of X-rays/MRI/CT scans; * Painful vertebral fracture with bone oedema on MRI and at least NRS \>4 units; * At least 12 months of follow-up.

Exclusion criteria

* VCF associated with metastatic lesions and myeloma; * Neurological impairment with compression of the spinal cord or nerves; * General contraindications to surgery.

Design outcomes

Primary

MeasureTime frame
NRS (Numerical Rating Scale)between baseline (pre-operative) and 1-year follow-up
ODI (Oswestry Disability Index)between baseline (pre-operative) and 1-year follow-up

Secondary

MeasureTime frameDescription
adverse events (AEs), serious adverse events (SAEs) and adverse device events (ADEs)postoperatively, at 1 month and at 1 year
NRS (Numerical Rating Scale)baseline (pre-operative) and immediate post-operative and 1-month follow-ups
Kyphotic Angle (KA)post-operative and 1-year follow-up
Wedge Angle (WA)post-operative and 1-year follow-up
vertebral body height (VBH)baseline, immediate post-operative and 1-year follow-upvertebral body height (VBH) in the anterior, middle and posterior projections

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026